Phase II study of carboplatin (CBDCA) and irinotecan (CPT-11) for patients with cancer of unknown primary (CUP)

被引：1
|
作者：
Ando, M., Sr.
Yonemori, K.
Yunokawa, M.
Nakano, E.
Kouno, T.
Shimizu, C.
Katsumata, N.
Tamura, K.
Arioka, H.
Fujiwara, Y.
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Yokohama Ind Accid Hosp, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.13514
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13514
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer
    Tsunoda, A.
    Yasuda, N.
    Nakao, K.
    Narita, K.
    Yamazaki, K.
    Watanabe, M.
    Suzuki, N.
    Kusano, M.
    ONCOLOGY, 2007, 72 (1-2) : 58 - 63
  • [32] Phase II study of irinotecan (CPT-11) in patients with advanced colorectal cancer resistant to 5-fluorouracil based chemotherapy.
    Salinas, P
    Lara, MA
    de Septién, CFM
    Feliu, J
    Espinosa, E
    de Castro, J
    García-Girón, C
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S76 - S76
  • [33] Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU):: A phase II study
    Antón, A
    Aranda, E
    Carrato, A
    Marcuello, E
    Massutti, B
    Cervantes, A
    Abad, A
    Sastre, J
    Fenández-Martos, C
    Gallén, M
    Díaz-Rubio, E
    Huarte, L
    Balcells, M
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (08): : 639 - 643
  • [34] Final results of a multicenter phase II study of irinotecan (CPT-11) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Boige, V
    Taieb, J
    Hebbar, M
    Magherini, E
    Mignard, D
    Debaere, T
    Hannoun, L
    Tigaud, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 358S - 358S
  • [35] Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors
    Font, A
    Sanchez, JM
    Rosell, R
    Taron, M
    Martinez, E
    Guillot, M
    Manzano, JL
    Margeli, M
    Barnadas, A
    Abad, A
    LUNG CANCER, 2002, 37 (02) : 213 - 218
  • [36] A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma
    Rothenberg, ML
    Cox, JV
    DeVore, RF
    Hainworth, JD
    Pazdur, R
    Rivkin, SE
    Macdonald, JS
    Geyer, CE
    Sandbach, J
    Wolf, SL
    Mohrland, JS
    Elfring, GL
    Miller, LL
    Von Hoff, DD
    CANCER, 1999, 85 (04) : 786 - 795
  • [37] Phase I and pharmacokinetic study of irinotecan (CPT-11) administered with cyclosporine A (CSA).
    Fagbemi, S
    Ratain, MJ
    Iyer, L
    Mani, S
    Vogelzang, NJ
    Wang, X
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 163 - 163
  • [38] A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer
    Manabu Shiozawa
    Nobuhiro Sugano
    Kazuhito Tsuchida
    Soichiro Morinaga
    Makoto Akaike
    Yukio Sugimasa
    Journal of Cancer Research and Clinical Oncology, 2009, 135 : 365 - 370
  • [39] A phase II study with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) in patients with metastatic colorectal cancer
    Destefanis, M
    Dalla Mola, A
    Ostellino, O
    Capello, C
    Milanesi, E
    Grillo, C
    Castiglione, F
    Venturino, A
    Porcile, G
    ANNALS OF ONCOLOGY, 2000, 11 : 67 - 67
  • [40] A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
    N E Schoemaker
    I E L M Kuppens
    V Moiseyenko
    B Glimelius
    M Kjaer
    H Starkhammer
    D J Richel
    R Smaaland
    K Bertelsen
    J P Poulsen
    E Voznyi
    J Norum
    D Fennelly
    K M Tveit
    A Garin
    G Gruia
    A Mourier
    D Sibaud
    P Lefebvre
    J H Beijnen
    J H M Schellens
    W W ten Bokkel Huinink
    British Journal of Cancer, 2004, 91 : 1434 - 1441
12345